26 completed, 1 unknown. 22 Phase 3, 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 22 | Completed 21, Unknown 1 |
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 1 | Completed 1 |
Follow Hiberix: new trials by email Literature Review of Hiberix trials Research Report on Hiberix
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) V114, Prevnar 13™, RotaTeq™ - Pneumococcal Infections, Pneumococcal Vaccines | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1720 | 2019-06-19 | 2023-07-28 |
| A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) Prevnar 13™, V114, RotaTeq™ - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 900 | 2018-10-18 | 2023-01-17 |
| Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 1196 | 2018-07-27 | 2026-08-20 |
| This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine Rotarix, Pediarix, Hiberix - Rotavirus Infection, Rotavirus Vaccines | Phase 3 | Completed | GlaxoSmithKline | 1280 | 2017-09-14 | 2020-12-29 |
| Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine，Freeze-dried Minhai-HIB, Act-HIB® - Haemophilus Influenzae Type b Infections | Phase 3 | Unknown | Beijing Minhai Biotechnology Co., Ltd | 1560 | 2014-09-01 | 2015-09-25 |
| Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants Infanrix hexa, Pediarix, ActHIB - Poliomyelitis, Diphtheria | Phase 3 | Completed | GlaxoSmithKline | 585 | 2014-04-16 | 2019-11-27 |
| Single-center Study Evaluating the Safety and Efficacy of Viscogel® as Adjuvant in Act-HIB® Vaccine 0.2μg Act-HIB®, ViscoGel® and 0.2μg Act-HIB®, ViscoGel® and 2μg Act-HIB® - Healthy | Phase 1 / Phase 2 | Completed | Viscogel AB | 130 | 2012-03-01 | 2013-08-30 |
| Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine Infanrix™-IPV+Hib, Infanrix™ IPV, Hiberix™ - Poliomyelitis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 454 | 2011-03-04 | 2019-11-27 |
| Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), ActHIB™, Pentacel™ - Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 4003 | 2010-06-18 | 2018-07-12 |
| A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants DTaP//PRP-T Combined Vaccine, DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi | 1056 | 2010-01-01 | 2011-12-13 |
| Study in Toddlers (12-18 Months) Comparing a Booster Dose of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b Infections in China Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine), Hiberix (Haemophilus influenzae type b (Hib) vaccine) - Haemophilus Influenzae Type b (Hib) Infection | Phase 3 | Completed | Novartis Vaccines | 846 | 2009-09-01 | 2011-12-08 |
| Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age Pneumococcal conjugate vaccine GSK1024850A, Tritanrix-HepB/Hib, Hiberix - Infections, Streptococcal, Streptococcus Pneumoniae | Phase 3 | Completed | GlaxoSmithKline | 360 | 2009-03-07 | 2020-01-03 |
| Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children Infanrix™, Hiberix™ - Acellular Pertussis, Diphtheria | Phase 3 | Completed | GlaxoSmithKline | 467 | 2008-06-07 | 2018-06-06 |
| Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines Synflorix, Tritanrix-HepB, Hiberix - Infections, Streptococcal | Phase 3 | Completed | GlaxoSmithKline | 756 | 2007-10-22 | 2019-01-14 |
| Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib Zilbrix-Hib, Tritanrix™-HepB/ Hiberix™ - Whole Cell Pertussis, Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 300 | 2007-06-01 | 2017-08-18 |
| Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib, Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi | 792 | 2007-03-01 | 2012-04-17 |
| Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib. Infanrix™/Hib, Infanrix, Hiberix - Tetanus, Diphtheria | Phase 3 | Completed | GlaxoSmithKline | 660 | 2007-01-03 | 2018-06-06 |
| Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine Pneumococcal conjugate vaccine GSK1024850A, Prevenar, Tritanrix-HepB - Infections, Streptococcal | Phase 3 | Completed | GlaxoSmithKline | 806 | 2006-08-07 | 2018-12-07 |
| Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years. Haemophilus influenzae type b and meningococcal serogroup C (vaccine), Priorix™, Hiberix™ - Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 3 | Completed | GlaxoSmithKline | 433 | 2006-06-01 | 2018-08-24 |
| Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects Tritanrix™- HepB, Hiberix™, Mencevax™ ACW - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 168 | 2006-04-19 | 2018-06-06 |
Showing 20 of 27. Sign in to see all of them.
Haemophilus Infections (14) · Tetanus (12) · Diphtheria (10) · Hepatitis B (7) · Whooping Cough (7) · Pneumococcal Infections (5) · Meningococcal Infections (4) · Poliomyelitis (4) · Meningitis (3) · Streptococcal Infections (3) · Gram-Negative Bacterial Infections (1) · Infections (1) · Malaria (1) · Meningitis, Meningococcal (1) · Rotavirus Infections (1)
GlaxoSmithKline (18) · Merck Sharp & Dohme LLC (2) · Sanofi (2) · Beijing Minhai Biotechnology Co., Ltd (1) · Novartis Vaccines (1) · Sanofi Pasteur, a Sanofi Company (1) · Uppsala University (1) · Viscogel AB (1)
China (6) · United States (6) · Philippines (5) · Puerto Rico (3) · India (2) · Poland (2) · Thailand (2) · Turkey (Türkiye) (2) · Australia (1) · Mozambique (1) · South Africa (1) · South Korea (1) · Sweden (1) · United Kingdom (1)
PMID 16417952, PMID 19325447, PMID 19325451, PMID 19325452, PMID 20657177, PMID 21219984, PMID 21443960, PMID 22001281, PMID 22349525, PMID 25008901, PMID 25218298, PMID 28069358, PMID 36522265, PMID 36621410, PMID 37846456
2016 (2), 2018 (2)